ERBB-2 Bispecific Antibody Combination Therapy Patent
Summary
The European Patent Office published EP3600412A1 for Merus B.V., covering a combination therapy using ERBB-2 targeting agents with bispecific antibodies that bind epitopes on both ERBB-2 and ERBB-3 extracellular domains for treating ERBB-2 and ERBB-2/ERBB-3 positive tumors. The patent application names four inventors and designates all major European contracting states.
What changed
Merus B.V. obtained publication of EP3600412A1, a European patent application for a therapeutic combination comprising an ERBB-2 targeting agent and a bispecific antibody with binding sites for both ERBB-2 and ERBB-3 extracellular epitopes. The invention is directed to methods of treating individuals with ERBB-2 or ERBB-2/ERBB-3 positive tumors using this combination therapy.
No immediate compliance action is required. Pharmaceutical companies developing similar HER2/ERBB-2 targeting therapies should review this patent publication to assess potential freedom-to-operate considerations in European markets. Biotech firms and researchers in the bispecific antibody space should monitor this IP position when developing competing products targeting the ERBB-2/ERBB-3 signaling pathway.
Source document (simplified)
COMBINATION OF ERBB-2 TARGETING AGENT AND A BISPECIFIC ANTIBODY THAT COMPRISES AN ANTIGEN-BINDING SITE THAT CAN BIND AN EPITOPE ON AN EXTRACELLULAR PART OF ERB-2 AND AN ANTIGEN-BINDING SITE THAT CAN BIND AN EPITOPE ON EXTRACELLULAR PART OF ERBB-3, FOR USE IN A METHOD OF TREATMENT OF AN INDIVIDUAL THAT HAS ERBB-2, ERBB-2/ERBB-3 POSITIVE TUMOUR
Publication EP3600412A1 Kind: A1 Mar 25, 2026
Applicants
Merus B.V.
Inventors
THROSBY, Mark, GEUIJEN, Cecilia Anna Wilhelmina, MAUSSANG-DETAILLE, David Andre Baptiste, LOGTENBERG, Ton
IPC Classifications
A61K 39/395 20060101AFI20181005BHEP C07K 16/28 20060101ALI20181005BHEP C07K 16/32 20060101ALI20181005BHEP C07K 16/46 20060101ALI20181005BHEP C07K 16/30 20060101ALI20181005BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.